



rippletherapeutics

Keeping Patients In Sight

Overview of the Epidel[®] Prodrug Engineered
Sustained Drug Delivery Platform

Wendy Naimark, CTO & Cofounder

Ripple's Unique Approach

NO POLYMER


ONLY PRODRUG



Controlled release pharmaceuticals without polymers


Engineered Prodrugs with a Material Advantage

- Inherent processability
 - High drug loading
 - No inflammatory byproducts
 - Surface mediated drug release
 - No polymer residue
-




The Epidel[®] Advantage

Pharmacokinetics




Controlled drug release




Clinical Benefit



Reduced treatment burden



Commercialization



Composition of Matter




Core Features of Ripple's Epidel[®] Technology

Simple Chemistry




Ripple Prodrug Molecule

No polymers




100% Prodrug

Scalable Manufacturing




Surface Erosion



Simple Degradation




Tunable Release




Engineerable Drug release Kinetics and Duration

Effects of Formulation




Effects of Form Factor



Epidel Platform Design Features


Prodrug Design Inputs



Key Design Features

Drug Size	Small Molecules
Functional Groups for Conjugation	-OH, -COOH, -NH _x , -SH, -C=O
Material Properties	Processable prodrugs
Mechanism of Degradation	Hydrolyzeable linkages
Release Kinetics	Surface erosion (dissolution driven)


Established processes for efficient new drug evaluation



Ripple's Prodrug Engineering Versatility

Ripple has more than **fifty (50)** patents and patent applications

Includes granted composition of matter patents.




Demonstrated



Platform expansion


Ophthalmology Focused: Developing front & back of the eye solutions



- ❑ Eliminating the need for drops and reducing injection frequency
- ❑ Providing better outcomes for patients
- ❑ Easier management of care for physicians


Demonstrated Dexamethasone Prodrug Preclinical to Clinical translation

Preclinical Pharmacokinetics



Clinical
Translation

RIPPLE-1 Phase II 60 pt DME/RVO Study



Patient Tx History: 9 years anti-VEGF

Ripple Commercial Strategy

Balance of Proprietary Products and Partner Programs



RIPPLE
Proprietary
Products



**Funded
Partner
Programs**

**RIPL Internal
Development**

Intermediate Dry AMD

RTC – 4202 IVT
Complement
Inhibitor

RTC – 4001 IVT
Statin

**Product Licensing
Deals**

Glaucoma

RTC-620 IC
Bimatoprost

**Development Funding
with Licensing Option**

ripple

abbvie

GLAUKOS
TRANSFORMING VISION



www.rippletherapeutics.com

MaRS Centre, South Tower

101 College Street, Suite 300 Toronto,
ON M5G 1L7

T (416) 673-8168 F (416) 977-1329

